LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L studyHirotsugu Kenmotsu, Toshiaki Takahashi, Keita Mori et al.|Annals of Oncology|2021Cited by 17